IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function

Therapeutics that inhibit IL-6 at different points in its signaling pathway are in clinical use, yet whether the immunological effects of these interventions differ based on their molecular target is unknown. We performed short-term interventions in individuals with type 1 diabetes using anti–IL-6 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Speake, Cate, Habib, Tania, Lambert, Katharina, Hundhausen, Christian, Lord, Sandra, Dufort, Matthew J., Skinner, Samuel O., Hu, Alex, Kinsman, MacKenzie, Jones, Britta E., Maerz, Megan D., Tatum, Megan, Hocking, Anne M., Nepom, Gerald T., Greenbaum, Carla J., Buckner, Jane H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746808/
https://www.ncbi.nlm.nih.gov/pubmed/36282595
http://dx.doi.org/10.1172/jci.insight.159436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746808/
https://www.ncbi.nlm.nih.gov/pubmed/36282595
http://dx.doi.org/10.1172/jci.insight.159436

Ejemplares similares